Key facts
- RIGImmune’s last known valuation is $10.7M (Dec 2022).
- It has raised $8.7M; the latest was Later Stage VC ($1.8M) in Nov 2025.
- Notable investors include F-Prime Capital, Connecticut Innovations, Gates Foundation, Alembic Pharmaceuticals, Rivermount VC Fund — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for RIGImmune
- ·The full record, as it builds
Funding rounds
No funding rounds for RIGImmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RIGImmune
Operator of a biopharmaceutical research company intended to focus on the development of novel treatments for RNA viruses. The company's therapeutic candidates are designed to ameliorate a broad spectrum of disease conditions and therapeutic outcomes arising from viral infections and certain cancers, enabling doctors to treat viral respiratory infections as adjuvants or boosters.
- Sector
- Healthcare
- HQ
- Farmington, CT, United States
- Founded
- 2020
- Employees
- 12
- Website
- rigimmune.com/
- Ownership
- Privately Held (backing)
RIGImmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RIGImmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RIGImmune in its N-PORT filings yet. We sweep new filings monthly.